A major Scandinavian study by Karolinska Institutet shows that GLP-1 analogs, used in diabetes and obesity treatment, do not increase thyroid cancer risk, confirming their safety over nearly four years of observation. A comprehensive study by Karolinska Institutet found no evidence that GLP-1 analogs increase the risk of thyroid cancer. Analyzing data from over 435,000 patients across Scandinavia, the study compared GLP-1 users to those on other diabetes treatments over nearly four years, consistently showing no increased cancer risk.
This research is part of a broader investigation into the real-world effects of newer diabetes medications. GLP-1 analogs, drugs widely used for treating diabetes and obesity, have raised concerns about potentially increasing thyroid cancer risk. However, a comprehensive Scandinavian study conducted by researchers from Karolinska Institutet has found no evidence supporting this connection.
The findings are published in The BMJ . GLP-1 receptor agonists, also known as GLP-1 analogs, reduce blood sugar levels and appetite. They are widely used in the treatment of type 2 diabetes and obesity, with their clinical use steadily increasing.
Earlier studies and adverse event data have suggested that these drugs could be associated with an increased risk of thyroid tumors. However, due to limitations in data and methodology, clear conclusions could not be drawn, leading to uncertainty about this potential side effect. “Many people take these medicines,.
